litlas
Log inCreate account

S A Rosenberg

Active 1980–2001

75
Papers
19,982
Citations
75
h-index
75
i10-index

Citations

Citations per year for S A Rosenberg1981: 4 citations1982: 4 citations1983: 4 citations1984: 20 citations1985: 27 citations1986: 49 citations1987: 68 citations1988: 84 citations1989: 52 citations1990: 78 citations1991: 97 citations1992: 91 citations1993: 111 citations1994: 104 citations1995: 131 citations1996: 147 citations1997: 186 citations1998: 179 citations1999: 192 citations2000: 173 citations2001: 155 citations2002: 161 citations2003: 135 citations2004: 132 citations2005: 119 citations2006: 94 citations2007: 89 citations2008: 89 citations2009: 92 citations2010: 105 citations2011: 81 citations2012: 65 citations2013: 63 citations2014: 74 citations2015: 67 citations2016: 62 citations2017: 85 citations2018: 87 citations2019: 200 citations2020: 191 citations2021: 187 citations2022: 140 citations2023: 83 citations2024: 119 citations2025: 62 citations2026: 1 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,076 citing papers, 42.5% of this breakdownGermany: 283 citing papers, 5.8% of this breakdownItaly: 269 citing papers, 5.5% of this breakdownUnited Kingdom: 226 citing papers, 4.6% of this breakdownChina: 197 citing papers, 4% of this breakdownFrance: 190 citing papers, 3.9% of this breakdownCanada: 168 citing papers, 3.4% of this breakdownNetherlands: 156 citing papers, 3.2% of this breakdownAustralia: 132 citing papers, 2.7% of this breakdownJapan: 131 citing papers, 2.7% of this breakdownSwitzerland: 123 citing papers, 2.5% of this breakdownBelgium: 91 citing papers, 1.9% of this breakdown
0%42.5%Other 17.3%

Institutions

Fields

  • Medicine54.7%
  • Immunology and Microbiology33.2%
  • Biochemistry, Genetics and Molecular Biology9.3%
  • Engineering0.5%
  • Neuroscience0.5%
  • Agricultural and Biological Sciences0.3%
  • Other1.5%

Topics

  • Immunotherapy and Immune Responses13.7%
  • Immune Cell Function and Interaction7.7%
  • CAR-T cell therapy research7.5%
  • Cancer Immunotherapy and Biomarkers6.3%
  • T-cell and B-cell Immunology4.8%
  • Sarcoma Diagnosis and Treatment3.4%
  • Other56.6%

Coauthors

All papers

Open in search
  1. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

    Authors: G. Fyfe, Richard I. Fisher, S A Rosenberg, Mario Sznol, David Parkinson, Arthur C. Louie - Journal of Clinical Oncology 1995 cited by 1,388

  2. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.

    Authors: Jin Yang, Alfred E. Chang, A Baker, William F. Sindelar, David N. Danforth, Suzanne L. Topalian, Thomas F. DeLaney, Eli Glatstein, Seth M. Steinberg, Maria J. Merino, S A Rosenberg - Journal of Clinical Oncology 1998 cited by 1,531

  3. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

    Authors: S A Rosenberg, James J. Mulé, Paul J. Spiess, Cheryl M. Reichert, S. Schwarz - The Journal of Experimental Medicine 1985 cited by 741

  4. Loss of Functional Beta2-Microglobulin in Metastatic Melanomas From Five Patients Receiving Immunotherapy

    Authors: Nicholas P. Restifo, Franco Marincola, Yutaka Kawakami, Jeffrey K. Taubenberger, John R. Yannelli, S A Rosenberg - JNCI Journal of the National Cancer Institute 1996 cited by 529

  5. The fate of interleukin-2 after in vivo administration.

    Authors: J H Donohue, S A Rosenberg - The Journal of Immunology 1983 cited by 373

  6. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

    Authors: Tim Lister, D. Crowther, S.B. Sutcliffe, Eli Glatstein, G P Canellos, Robert C. Young, S A Rosenberg, Charles A. Coltman, M Tubiana - Journal of Clinical Oncology 1989 cited by 1,628

  7. Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer

    Authors: S A Rosenberg, Michael T. Lotze, Jin‐Hao Yang, Suzanne L. Topalian, A. E. Chang, Douglas J. Schwartzentruber, Paul Aebersold, S.F. Leitman, W. Marston Linehan, Claudia A. Seipp, D. E. White, Seth M. Steinberg - JNCI Journal of the National Cancer Institute 1993 cited by 642

  8. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

    Authors: Yutaka Kawakami, S Eliyahu, Kazuyasu Sakaguchi, Paul Robbins, Licia Rivoltini, John R. Yannelli, Ettore Appella, S A Rosenberg - The Journal of Experimental Medicine 1994 cited by 865

  9. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.

    Authors: Beth Fisher, Beverly S. Packard, E.J. Read, Jorge A. Carrasquillo, C. Carter, S L Topalian, Jiacai Yang, P Yolles, S M Larson, S A Rosenberg - Journal of Clinical Oncology 1989 cited by 333

  10. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

    Authors: Ilana Yron, Turner A. Wood, Paul J. Spiess, S A Rosenberg - The Journal of Immunology 1980 cited by 264

  11. Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma

    Authors: Mark E. Dudley, John R. Wunderlich, Michael I. Nishimura, David C. Yu, James C. Yang, Suzanne L. Topalian, Douglas J. Schwartzentruber, Patrick Hwu, Francesco M. Marincola, Richard M. Sherry, Susan F. Leitman, S A Rosenberg - Journal of Immunotherapy 2001 cited by 357

  12. In Vivo Antitumor Activity of Tumor-Infiltrating Lymphocytes Expanded in Recombinant Interleukin-2

    Authors: Paul J. Spiess, James C. Yang, S A Rosenberg - JNCI Journal of the National Cancer Institute 1987 cited by 258

  13. Patterns of recurrence in patients with high-grade soft-tissue sarcomas.

    Authors: David A. Potter, Jerry Glenn, Timothy J. Kinsella, E Glatstein, Ernest E. Lack, Carlos S. Restrepo, D E White, Claudia A. Seipp, Robert Wesley, S A Rosenberg - Journal of Clinical Oncology 1985 cited by 379

  14. Human tumor antigens for cancer vaccine development

    Authors: Rong‐Fu Wang, S A Rosenberg - Immunological Reviews 1999 cited by 307

  15. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.

    Authors: Franco Marincola, Peter Shamamian, Richard B. Alexander, James R. Gnarra, Regina L. Turetskaya, С А Недоспасов, Toni B. Simonis, Jeffery K. Taubenberger, John R. Yannelli, Arnold Mixon, N P Restifo, M Herlyn, S A Rosenberg - The Journal of Immunology 1994 cited by 168

  16. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.

    Authors: Suzanne L. Topalian, D. Solomon, S A Rosenberg - The Journal of Immunology 1989 cited by 520

  17. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.

    Authors: Jeffrey S. Weber, Michael L. Salgaller, Dvorit Samid, Brett A. Johnson, Meenhard Herlyn, Norman J. Lassam, Jonathan Treisman, S A Rosenberg - 1994 cited by 296

  18. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

    Authors: Licia Rivoltini, Yutaka Kawakami, Kazushige Sakaguchi, Scott Southwood, Alessandro Sette, Paul Robbins, Francesco M. Marincola, Michael L. Salgaller, John R. Yannelli, Ettore Appella, S A Rosenberg - The Journal of Immunology 1995 cited by 294

  19. In Vivo Distribution of Adoptively Transferred Indium- 111- Labeled Tumor Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Patients With Metastatic Melanoma

    Authors: Kean D. Griffith, E.J. Read, Jorge A. Carrasquillo, C. S. Carter, James C. Yang, Beth Fisher, Paul Aebersold, Beverly S. Packard, M. Y. Yu, S A Rosenberg - JNCI Journal of the National Cancer Institute 1989 cited by 184

  20. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.

    Authors: R B Cameron, Paul J. Spiess, S A Rosenberg - The Journal of Experimental Medicine 1990 cited by 116

  21. The Use of Melanosomal Proteins in the Immunotherapy of Melanoma

    Authors: Yutaka Kawakami, Paul Robbins, Rong Fu Wang, Maria R. Parkhurst, Xiaoqiang Kang, S A Rosenberg - Journal of Immunotherapy 1998 cited by 99

  22. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

    Authors: A Mazumder, S A Rosenberg - The Journal of Experimental Medicine 1984 cited by 371

  23. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases

    Authors: Kari R. Irvine, J. Babu Rao, S A Rosenberg, Nicholas P. Restifo - The Journal of Immunology 1996 cited by 238

  24. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.

    Authors: M T Lotze, Bruce R. Line, Douglas J. Mathisen, S A Rosenberg - The Journal of Immunology 1980 cited by 222